Despite government efforts to prop up biopharma and med-tech research toward creating women’s health products, companies must eventually reach out to the private markets to bring their inventions to ...

Many studies have linked the presence of specific bacteria to various diseases. But a general overgrowth of gut bacteria can be a symptom of different conditions, including colorectal cancer and ...

Organox Ltd. and Egenesis Inc. signed an agreement to advance a liver support system to facilitate liver recovery in the acute setting.

At the BioFuture 2024 conference held in New York in November, Seema Kumar, the CEO of Cure, described women’s health as something that has been directed at the “bikini area.” That “bikini” bias ...

Eko Health Inc. recently won a category III CPT code for its Sensora platform for cardiovascular disease detection. While a “cat III” CPT code hasn’t traditionally excited industry, the company is ...

WDR45 is located on the X chromosome. Its pathogenic variants are associated with various neurodegenerative disorders that are predominantly reported in females and present a wide range of clinical ...

The next-generation farnesyl transferase inhibitor KO-2806 is currently in phase I clinical development at Kura Oncology Inc. for the treatment of patients with solid tumors, including non-small-cell ...

Artbio Inc. and 3B Pharmaceuticals GmbH have signed a worldwide, exclusive license and research agreement to develop an advanced preclinical stage first-in-class peptide α-radioligand therapy for the ...

ENPP1 contributes to establishing an immunosuppressive tumor microenvironment by blocking the cyclic GMP-AMP synthase (cGAS)-stimulator of interferon genes (STING) signaling, which is critical in ...

PTC Therapeutics Inc.’s accelerated go-ahead from the U.S. FDA for Kebilidi (eladocagene exuparvovec-tneq), a recombinant adeno-associated virus serotype 2-based gene therapy to treat aromatic L-amino ...

Enveda Therapeutics Inc. has received U.S. IND clearance and advanced into phase I trials with ENV-294, its naturally derived anti-inflammatory.

Chia Tai Tianqing Pharmaceutical Group Co. Ltd. has synthesized compounds acting as tyrosine-protein kinase receptor UFO (AXL) inhibitors reported to be useful for the treatment of cancer.